Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Recurrence × vistusertib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Recurrence 1 Prostatic Neoplasms 1 Muscle Invasive Bladder Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Glioblastoma 1 Disease 1 Breast Neoplasms 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1 Advanced Cancer 1

Interventions

Cyclophosphamide 39 fludarabine 28 Dexamethasone 20 venetoclax 19 Cytarabine 16 Rituximab 13 pembrolizumab 12 fludarabine phosphate 12 Filgrastim 12 Gemcitabine 10 Etoposide 10 Granulocyte Colony-Stimulating Factor 9 carfilzomib 8 Vincristine 8 Topotecan 8 Interleukin-2 8 Decitabine 8 Nivolumab 7 Melphalan 7 Lenalidomide 7 Everolimus 7 Doxorubicin 7 Azacitidine 7 pomalidomide 6 Vorinostat 6 Carboplatin 6 Calcium Dobesilate 6 Bortezomib 6 obinutuzumab 5 ibrutinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02780830 2016-09-15

INHIBITOR

AstraZeneca

Phase 1 Withdrawn

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡